FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+5.37%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$1.5B
AUM Growth
+$1.5B
(-10%)
Cap. Flow
-$11.7M
Cap. Flow
% of AUM
-0.78%
Top 10 Holdings %
Top 10 Hldgs %
63.15%
Holding
55
New
7
Increased
10
Reduced
5
Closed
4
Top Buys
| 1 |
Mirum Pharmaceuticals
MIRM
|
$66.7M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$28.7M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$23.4M |
| 4 |
AN2 Therapeutics
ANTX
|
$22.3M |
| 5 |
BridgeBio Pharma
BBIO
|
$19.4M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Mirum Pharmaceuticals
MIRM
$3.71B
| $204M | 13.58% | 6,470,392 +2,110,285 | +48% | +$66.7M |
|
2
HilleVax
HLVX
$105M
| $132M | 8.74% | 9,781,472 | – | – |
|
3
Krystal Biotech
KRYS
$4.27B
| $115M | 7.62% | 988,460 -1,800 | -0.2% | -$209K |
|
4
NewAmsterdam Pharma
NAMS
$2.71B
| $112M | 7.45% | 12,131,705 +1,259,902 | +12% | +$11.7M |
|
5
Phathom Pharmaceuticals
PHAT
$864M
| $105M | 6.96% | 10,109,279 | – | – |
|
|
6
BridgeBio Pharma
BBIO
$9.89B
| $71.9M | 4.77% | 2,725,949 +737,073 | +37% | +$19.4M |
|
7
Vaxcyte
PCVX
$4B
| $59.4M | 3.94% | 1,164,405 | – | – |
|
8
Rhythm Pharmaceuticals
RYTM
$6.85B
| $54.4M | 3.61% | 2,371,304 +204,082 | +9% | +$4.68M |
|
|
VRNA
9
Verona Pharma
VRNA
$9.16B
| $49.1M | 3.26% | 3,014,349 +70,000 | +2% | +$1.14M |
|
10
Crinetics Pharmaceuticals
CRNX
$2.92B
| $47.3M | 3.14% | 1,589,931 +175,108 | +12% | +$5.21M |
|
11
Arcutis Biotherapeutics
ARQT
$1.86B
| $46.1M | 3.06% | 8,684,232 | – | – |
|
|
ALPN
12
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $34.2M | 2.27% | 2,985,757 | – | – |
|
13
Tarsus Pharmaceuticals
TARS
$2.47B
| $31.8M | 2.11% | 1,787,527 | – | – |
|
14
KalVista Pharmaceuticals
KALV
$678M
| $31.2M | 2.07% | 3,238,859 | – | – |
|
15
Disc Medicine
IRON
$2.07B
| $30.8M | 2.04% | 655,000 | – | – |
|
|
16
Rocket Pharmaceuticals
RCKT
$354M
| $28.7M | 1.91% | +1,403,013 | New | +$28.7M |
|
17
Revolution Medicines
RVMD
$7.1B
| $27.6M | 1.83% | 997,455 +142,971 | +17% | +$3.96M |
|
|
18
Apellis Pharmaceuticals
APLS
$3.48B
| $23.4M | 1.55% | +614,043 | New | +$23.4M |
|
|
19
AN2 Therapeutics
ANTX
$30.1M
| $22.3M | 1.48% | +1,388,889 | New | +$22.3M |
|
20
Merus
MRUS
$4.98B
| $17.6M | 1.17% | 746,479 | – | – |
|
|
JBIO
21
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $16.4M | 1.09% | 1,204,867 +210,009 | +21% | +$2.85M |
|
22
AnaptysBio
ANAB
$569M
| $16.2M | 1.07% | 899,700 | – | – |
|
23
Savara
SVRA
$567M
| $15.1M | 1% | +4,000,000 | New | +$15.1M |
|
24
Trevi Therapeutics
TRVI
$883M
| $15M | 1% | 6,881,090 | – | – |
|
25
Cogent Biosciences
COGT
$1.69B
| $14.6M | 0.97% | 1,501,383 | – | – |
|